{"id":"W2150308444","doi":"10.1007/s10637-010-9444-0","title":"A dose-escalation phase I trial of nimotuzumab, an antibody against the epidermal growth factor receptor, in patients with advanced solid malignancies","year":2010,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":false,"ca_institutions":"Ontario Institute for Cancer Research; University of Toronto; University Health Network; Princess Margaret Cancer Centre","funders":"Académie française","keywords":"Nimotuzumab; Medicine; Toxicity; Epidermal growth factor receptor; Pharmacodynamics; Rash; Pharmacology; Internal medicine; Cetuximab; Pharmacokinetics; Phases of clinical research; Oncology; Monoclonal antibody; Antibody; Cancer; Immunology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004201066,0.0002044386,0.0003356471,0.0001967612,0.00009331027,0.00003014986,0.0002254925,0.0001246724,0.0001774843],"category_scores_gemma":[0.0009052597,0.0001424752,0.00006344522,0.0004892603,0.0004660014,0.000391217,0.00004113388,0.0004709996,0.00001486727],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001153996,"about_ca_system_score_gemma":0.001496825,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001917384,"about_ca_topic_score_gemma":0.00007036992,"domain_scores_codex":[0.9974778,0.000140044,0.0005594631,0.0003519516,0.001137914,0.0003328854],"domain_scores_gemma":[0.998332,0.0002438382,0.0002384517,0.0003749716,0.0004798551,0.0003308642],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.05001305,0.003299031,0.5521963,0.0002802622,0.0001539717,0.00001241713,0.00722564,0.0002631521,0.334096,0.003698073,0.002456818,0.04630536],"study_design_scores_gemma":[0.1453184,0.00357391,0.8036984,0.0004724739,0.00003810875,0.000003443376,0.0002089942,0.001052092,0.04119474,0.001861366,0.002155954,0.0004220704],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9949707,0.00001390495,0.00003602024,0.002809201,0.0002965807,0.001419421,0.00008349289,0.00003553033,0.0003350854],"genre_scores_gemma":[0.9955344,0.000009862081,0.002725875,0.0005340096,0.0004058341,0.0000570039,0.0005815571,0.0000363863,0.0001150879],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2929012,"threshold_uncertainty_score":0.5809968,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02755508365146138,"score_gpt":0.3533887031160662,"score_spread":0.3258336194646049,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}